Definium Therapeutics, Inc. (DFTX) — Financial statements
Income statement, balance sheet, and cash flow for Definium Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.53↓83.3% | 3 | 0.00 | 0.00 | |
| Gross Profit | 0.00↑100.0% | -0.53↑83.3% | -3 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 118↑80.2% | 65↑33.4% | 49↑35.4% | 36↑4.0% | 35 | |
| General & Administrative Expenses | 49↑26.0% | 39↓7.5% | 42↑38.4% | 30↓48.9% | 59 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 49↑26.0% | 39↓7.5% | 42↑38.4% | 30↓48.9% | 59 | |
| Other Expenses | 0.00↑100.0% | -0.53 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 166↑60.9% | 103↑14.0% | 91↑36.7% | 66↓29.3% | 94 | |
| Total Costs & Expenses | 166↑60.0% | 104↑10.7% | 94↑41.5% | 66↓29.3% | 94 | |
| Operating Results | ||||||
| Operating Income | -166↓60.0% | -104↓10.7% | -94↓41.5% | -66↑29.3% | -94 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.53↓83.3% | 3↓0.6% | 3↑21.6% | 3 | |
| EBITDA | -178↓68.4% | -106↓14.4% | -93↓46.6% | -63↑30.8% | -91 | |
| EBIT | -178↓67.6% | -106↓11.1% | -96↓44.3% | -66↑29.3% | -94 | |
| Interest & Other Income | ||||||
| Net Interest Income | 5↓40.9% | 9↑98.9% | 5 | 0.00↑100.0% | -0.36 | |
| Interest Income | 11↓5.2% | 12↑107.0% | 6↑273.5% | 1 | 0.00 | |
| Interest Expense | 5↑140.1% | 2↑148.2% | 0.92↓38.5% | 1↑316.4% | 0.36 | |
| Non-Operating Income | 12↑384.0% | 2↑32.9% | 2 | 0.00 | 0.00 | |
| Other Income / Expenses | -17↓267.1% | -5↓155.3% | -2↓119.6% | 10↑2912.7% | -0.34 | |
| Income Before Tax | -184↓69.1% | -109↓13.5% | -96↓68.6% | -57↑39.7% | -94 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -1 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -184↓69.1% | -109↓13.5% | -96↓68.6% | -57↑39.0% | -93 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -184↓69.1% | -109↓13.5% | -96↓68.6% | -57↑39.0% | -93 | |
| Bottom-Line Net Income | -184↓69.1% | -109↓13.5% | -96↓68.6% | -57↑39.0% | -93 | |
| EPS (Basic) | -2.06↓33.8% | -1.54↑36.9% | -2.44↓59.5% | -1.53↑55.0% | -3.40 | |
| EPS (Diluted) | -2.06↓1273.3% | -0.15↑93.9% | -2.44↓59.5% | -1.53↑55.0% | -3.40 | |
| Weighted Average Shares | 89↑26.8% | 70↑79.9% | 39↑26.9% | 31↑12.7% | 27 | |
| Weighted Average Diluted Shares | 89↓87.3% | 705↑1699.4% | 39↑26.9% | 31↑12.7% | 27 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.